awmsg logo



lacosamide (Vimpat®)


Reference No. 3343

Publication date:
06/03/2018


Appraisal information

lacosamide (Vimpat®) 50 mg film-coated tablet
lacosamide (Vimpat®) 100 mg film-coated tablet
lacosamide (Vimpat®) 150 mg film-coated tablet
lacosamide (Vimpat®) 200 mg film-coated tablet


Company: UCB Pharma Ltd
BNF category: Central nervous system
NMG meeting date: 10/01/2018
AWMSG meeting date: 14/02/2018
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 0318
Ratification by Welsh Government: 05/03/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Lacosamide (Vimpat®) is recommended as an option for use within NHS Wales as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in children from ≥ 4 years of age to ≤ 15 years of age with epilepsy.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download